MetALD: New Perspectives on an Old Overlooked Disease DOI Creative Commons
Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga

и другие.

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 3, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.

Язык: Английский

Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults DOI Creative Commons

Yeongmin Kim,

Taesic Lee, Chang‐Myung Oh

и другие.

BMC Gastroenterology, Год журнала: 2025, Номер 25(1)

Опубликована: Фев. 24, 2025

This study investigated the prevalence and causal relationships of chronic metabolic diseases (diabetes, hypertension, dyslipidemia) with steatotic liver disease (SLD), specifically metabolically associated alcoholic (MetALD). We conducted a comprehensive analysis using cross-sectional data from KNHANES 2011 to 2021 NHANES 1999 2020. Longitudinal 2001 2014 KoGES were used. Participants categorized into dysfunction-associated SLD(MASLD), MetALD, ALD groups based on their hepatic steatosis index (HSI), including profiles, body composition, diabetes, alcohol consumption. Multivariable, age smoking status, logistic Cox regression analyses performed assess incidence diseases. In both cohorts, an increased HSI was significantly higher cohort showed that MASLD MetALD significant predictors in men women. hazard ratio for development than analysis. highlighted intertwined nature SLD health, emphasis role MetALD. The association between underscores need integrated management strategies address health risk factors.

Язык: Английский

Процитировано

0
MetALD: New Perspectives on an Old Overlooked Disease DOI Creative Commons
Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga

и другие.

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 3, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.

Язык: Английский

Процитировано

0